Treatment

Treatment :

1. Drug Treatment

  • Four medications have received marketing authorization in France. Three are central acetylcholinesterase inhibitors (which increase the bioavailability of acetylcholine in the brain): donepezil, rivastigmine, and galantamine. The fourth, memantine, is an NMDA glutamate receptor antagonist. All are available in generic form.
  • These treatments are administered orally. Rivastigmine is also available as a transdermal patch.
  • Current indications are limited to the dementia stages of the disease (mild to moderately severe).
  • Clinical trials show that cognitive decline is slightly less pronounced in treated patients. These treatments may also improve certain behavioral symptoms (apathy, agitation, hallucinations).
  • The main side effects of acetylcholinesterase inhibitors are gastrointestinal disorders (nausea, vomiting, diarrhea, weight loss) and muscle cramps.
  • Due to their pharmacological action, cholinesterase inhibitors may have vagotonic effects on heart rate (e.g., bradycardia), especially in patients with supraventricular conduction disorders (sick sinus syndrome, sinoatrial or atrioventricular block), increasing the risk of syncope and falls. Contraindications and precautions must be strictly respected. A systematic ECG, and cardiology consultation if necessary, are required before prescription, along with careful monitoring, particularly of heart rate.
  • Initiation of treatment must be performed by a neurologist, psychiatrist, or geriatrician.
  • Due to their modest symptomatic efficacy, the French National Authority for Health (HAS) considered their benefit insufficient relative to their risks and recommended full withdrawal of reimbursement, effective since August 1, 2018. These treatments may still be prescribed under the conditions outlined above but are at the patient’s expense.
  • Other medications aim to limit behavioral disorders and mainly include psychotropic drugs, which must be used with great caution.
  • Medications that may worsen cognitive impairment should be reduced or discontinued whenever possible.

Non-Drug Treatment

Cognitive Stabilization or Compensation

  • Cognitive rehabilitation or remediation sessions with a speech therapist (by prescription).
  • Cognitive rehabilitation programs aimed at maintaining or restoring autonomy in daily tasks, provided by specialized Alzheimer teams (ESA) composed of psychomotor therapists, occupational therapists, and gerontology care assistants (by prescription), for mild to moderate stages.
  • Cognitive stimulation in medicalized day-care centers, upon registration.

Human Support and Third-Party Assistance

  • Support for caregivers, including home care services (home care aides, nursing assistants).
  • In cases of significant loss of autonomy or complex situations (e.g., individuals living alone and refusing care), recourse may be made to integrated care coordination systems (such as MAIA) to organize assistance and healthcare services.
  • Institutionalization when home care is no longer possible: medicalized nursing homes (EHPAD) or long-term care facilities.

Financial and Medico-Legal Support

  • Recognition as a long-term illness (ALD-15) with 100% coverage (dementia stage).
  • Financial support:
    • Personalized Autonomy Allowance (APA), subject to income and level of dependency, for individuals aged 60 and over;
    • Disability Compensation Benefit (PCH) for individuals under 60.
  • Legal protection measures such as safeguard of justice, guardianship, or family authorization, if necessary (not systematic).

Lifestyle Measures and Other Interventions

  • Daily physical activity (e.g., walking).
  • Daily outings.
  • Treatment of sensory impairments (hearing loss, visual disorders), which can worsen cognitive difficulties and social interaction.
  • Treatment of reversible aggravating factors (anemia, heart failure, pituitary insufficiency, sensory deficits, subdural hematoma, etc.).
  • Prevention of iatrogenesis, including discontinuation of non-essential psychotropic drugs.
  • In advanced stages of dementia, close monitoring of nutritional status is necessary due to frequent forgetting of meals.

Support for Caregivers

  • Caregiver support and respite platforms (psychological support, training).
  • Family and caregiver associations.

Objectives of These Measures

Most of these interventions aim to:

  • Prevent social withdrawal and lack of physical and cognitive stimulation;
  • Support families, who are often exhausted by the long-term management of the disease.

Diagnosis


Diagnosis

Diagnostic Approach

This is a diagnostic approach based not only on the presence of negative arguments, but above all on the collection of positive arguments.

  • Diagnosis during the patient’s lifetime is a diagnosis of probability. A definitive diagnosis relies on neuropathological examination (post-mortem).
  • The probability of making an accurate diagnosis depends on a combination of positive and negative findings. The greater the concordance between these arguments, the higher the diagnostic probability.
  • Diagnosis is based on five types of arguments:
  1. Positive clinical arguments: the profile of cognitive impairment.
  2. Neuroimaging arguments: negative findings (absence of other lesions) and positive findings (hippocampal atrophy).
  3. Negative arguments from blood tests, used to rule out differential diagnoses, particularly so-called reversible dementias.
  4. Positive metabolic imaging arguments (hypometabolism and/or hypoperfusion of associative cortices).
  5. Positive arguments from cerebrospinal fluid (CSF) biomarkers, showing a characteristic profile of intrathecal phosphorylated tau proteins.
  • In the vast majority of cases, the combination of clinical examination (including detailed cognitive assessment), brain MRI, and biological testing is sufficient to establish a diagnosis with high probability. Metabolic imaging and CSF biomarker analysis are not currently performed routinely.

Natural History of the Disease

Three progressive phases must be distinguished:

  • The pre-dementia or prodromal phase, marking the beginning of the symptomatic stage;
  • The dementia phase (mild to severe);
  • The very severe dementia phase.

a. Pre-dementia or Prodromal Phase

  • At this stage, patients remain autonomous for most activities of daily living.
  • The most frequent abnormality is a deficit in episodic memory consolidation:
    • This reflects severe involvement of the internal temporal regions (hippocampus and adjacent cortex).
    • Memory complaints are by far the most common symptom leading to suspicion of the diagnosis. This typically involves rapid forgetting (e.g., repeatedly asking the same questions), reflecting an inability to form lasting memories from lived events. Patients often minimize these complaints (anosognosia), while relatives are concerned.
  • During the five-word test, patients with episodic memory consolidation impairment are unable to recall the five words after a few minutes. Importantly, they are not helped by semantic cues, suggesting that the words were not encoded.
  • Neuropsychological memory assessment complements the evaluation, confirming impaired recall abilities (e.g., using the Free and Cued Selective Reminding Test – 16 items) and consolidation deficits. Patients may introduce intrusions (words not belonging to the original list).
  • This memory profile differs from memory impairments secondary to attention or executive dysfunction, which affect encoding or retrieval but not consolidation. In such cases, patients benefit from cues. This profile is commonly seen in depression, sleep disorders, anxiety, or excessive use of psychotropic medications.

b. Dementia Phase

  • Autonomy is significantly impaired in instrumental activities of daily living, such as using the telephone, transportation, managing medications, or handling finances.
  • In addition to memory impairment, other cognitive domains are affected to varying degrees, including aphasia, apraxia, agnosia, and executive dysfunction.
  • These deficits reflect the spread of lesions to associative cortical areas (prefrontal, parietal, and lateral temporal cortices).

c. Advanced Stage of the Disease (Severe Dementia)

  • Loss of autonomy is total due to impairment of basic activities of daily living (personal hygiene, dressing, mobility, feeding). Patients are often institutionalized. This phase precedes end of life and typically occurs 7 to 8 years after the first symptoms appear.
  • In addition to global cognitive impairment (which may include failure to recognize relatives), patients may present with psychological and behavioral disturbances (agitation or apathy, hallucinations, delusions, wandering, sleep and appetite disorders, sphincter control disorders), sleep–wake rhythm disturbances, malnutrition, and other neurological signs (gait and posture disorders with falls, epilepsy, myoclonus).
  • Death usually occurs due to general complications related to bedridden status (bronchopulmonary infections, complications following falls and prolonged immobilization) or sudden death.

Differential Diagnosis

1. Acute Confusional State (Delirium)

Important:
In older adults, delirium may reveal an underlying dementia or occur during its progression. Delirium does not rule out dementia; on the contrary, it should prompt further evaluation after recovery (approximately 6 months later) with a clinical and cognitive assessment.


2. Functional Causes of Neurocognitive Disorders

  • Depression, sleep disorders (insomnia and sleep apnea), chronic anxiety, and psychotropic medications (benzodiazepines, antidepressants, hypnotics, etc.) may cause attention and executive dysfunction impacting memory (“pseudo-amnesia”).
  • If cognitive impairment occurs in a depressive context, a full-dose antidepressant trial for a minimum of 3 monthsshould be considered.

3. Organic Causes

a. Secondary and Potentially Reversible Dementias

  • Hypothyroidism, vitamin B12 and/or folate deficiency, syphilis, progression of HIV infection, and certain brain tumors (e.g., frontal meningiomas).
  • Normal pressure hydrocephalus: characterized by gait disturbances (small-step gait), frontal-type cognitive impairment with apathy, and urinary incontinence. Brain CT or MRI shows tetraventricular enlargement without mass effect and periventricular fluid transudation. Diagnostic and therapeutic lumbar punctures may be performed, and ventriculo-peritoneal shunting is considered when diagnostic probability is high.
  • Chronic subdural hematoma: a frequent cause of cognitive impairment in the elderly, often detected long after minor head trauma. Risk factors include dehydration, chronic alcoholism, and anticoagulant therapy. CT or MRI reveals a crescent-shaped extra-axial fluid collection, often bilateral. Surgical evacuation or monitoring is considered on a case-by-case basis.
  • Vascular lesions due to small-vessel disease (hypertension, diabetes) include lacunes, white-matter hyperintensities, microbleeds, and small subcortical infarcts. Their accumulation may lead to vascular dementia or mixed dementia (vascular and Alzheimer’s).

If dementia progresses rapidly within less than one year, subacute encephalopathies should be considered, such as Creutzfeldt-Jakob disease or inflammatory/autoimmune encephalitis (including paraneoplastic syndromes).

Suitable Care Facilities for People with Alzheimer’s Disease

As Alzheimer’s disease progresses, the living environment plays a crucial role in the well-being, safety, and quality of life of affected individuals. Choosing an appropriate care setting helps support autonomy while ensuring proper medical and social care.

The Importance of an Adapted Environment

People with Alzheimer’s disease may experience memory loss, disorientation, and difficulties with daily activities. An adapted environment helps reduce anxiety, prevent accidents, and maintain a sense of familiarity and security. Calm surroundings, clear visual cues, and structured routines are essential.

Home-Based Care

In the early stages of the disease, many patients can continue living at home with appropriate support. Home-based care may include:

  • Assistance from home care aides or nurses
  • Adaptation of the living space to reduce risks (handrails, clear pathways, adequate lighting)
  • Day-care centers offering cognitive and social stimulation

This option allows patients to remain in a familiar environment while receiving necessary support.

Day Care Centers

Day care centers provide structured activities during the day for people with cognitive impairment. They offer cognitive stimulation, social interaction, and therapeutic activities in a safe setting. These centers also provide valuable respite for caregivers.

Specialized Nursing Homes

When home care is no longer possible, specialized nursing homes (such as Alzheimer units within medicalized nursing facilities) offer continuous care. These facilities provide:

  • 24-hour medical and nursing supervision
  • Trained staff specialized in Alzheimer’s care
  • Adapted spaces designed to reduce confusion and wandering

Such settings ensure safety while preserving dignity and comfort.

Long-Term Care Facilities

For patients in advanced stages of the disease, long-term care units provide comprehensive medical and daily support. These facilities focus on comfort, symptom management, and quality of life.

Supporting Families and Caregivers

Choosing the right care setting is often a difficult decision for families. Professional guidance, social services, and Alzheimer associations can help families understand available options and make informed choices.

Managing a confused patient :

Confusion is a frequent and distressing situation, particularly among older adults and people living with Alzheimer’s disease. Proper management is essential to ensure patient safety, reduce anxiety, and support caregivers.

Understanding Confusion

Confusion, also known as an acute confusional state or delirium, is characterized by a sudden change in mental status. It may include disorientation, impaired attention, memory difficulties, incoherent speech, or behavioral changes. In patients with Alzheimer’s disease, confusion can worsen existing cognitive deficits and significantly impact daily life.

Identifying the Causes

The first step in managing a confused patient is identifying the underlying cause. Confusion may result from:

  • Infections (urinary or respiratory infections, for example)
  • Dehydration or malnutrition
  • Medication side effects or drug interactions
  • Sleep deprivation
  • Pain or acute illness
  • Environmental changes or stress

Early identification of these factors allows for appropriate and timely intervention.

Ensuring Patient Safety

Safety is a priority in the care of a confused patient. Measures include:

  • Providing a calm, quiet, and familiar environment
  • Removing potential hazards to prevent falls
  • Ensuring adequate lighting, especially at night
  • Supervising the patient when necessary

These actions help reduce agitation and prevent accidents.

Communication and Reassurance

Clear and reassuring communication is essential. Caregivers should:

  • Speak slowly and use simple sentences
  • Maintain eye contact and a calm tone of voice
  • Reassure the patient frequently and explain actions clearly
  • Avoid confrontation or correcting the patient aggressively

A respectful and empathetic approach can significantly reduce anxiety and agitation.

Medical and Supportive Care

Management of confusion often requires a multidisciplinary approach. Treating the underlying cause is essential, while supportive care focuses on hydration, nutrition, pain management, and sleep regulation. Medication should be used cautiously and only when non-drug approaches are insufficient.

Supporting Caregivers

Caring for a confused patient can be physically and emotionally exhausting. Caregivers benefit from education, psychological support, and respite services. Understanding that confusion is a symptom and not intentional behavior helps reduce frustration and stress.

Progress in Alzheimer’s Research

Advances in Alzheimer’s Research

Alzheimer’s disease remains one of the most challenging neurological conditions, but research is progressing rapidly. Scientists around the world are working to better understand the disease and its causes, aiming to improve early detection and prevention strategies.

Understanding the Disease

Recent studies have clarified key biological mechanisms, including the accumulation of beta-amyloid plaques and tau protein tangles in the brain. This growing knowledge helps researchers identify the factors that contribute to the development and progression of Alzheimer’s.

Early Detection and Biomarkers

Advances in brain imaging and biomarkers are making it possible to detect Alzheimer’s before symptoms appear. Early detection allows for closer monitoring and more effective planning for care and prevention.

Genetics and Risk Factors

Research continues to explore genetic and environmental risk factors. Understanding these factors can help identify people at higher risk and provide insights into preventive measures.

Lifestyle and Prevention

Scientific studies also highlight the role of lifestyle in reducing risk. Regular physical activity, mental stimulation, a balanced diet, and social engagement have all been linked to lower chances of cognitive decline.

Looking Forward

While Alzheimer’s remains incurable, ongoing research is providing valuable insights into its causes, progression, and prevention. Each discovery brings us closer to a deeper understanding of the disease and better ways to support patients and society.